Answers are grounded in this paper and cite their sources.
ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV [Little SJ et al. N Engl J Med 2002;347:385] This is a multicenter study of resistance test results in HIV strains from untreated patients with acute HIV infection or seroconversion within the previous 6 months from May 1995 through June 2000 in 10 cities in the U.S. and Canada. Results were analyzed separately for 264 patients studied from 1995–98 and 113 patients studied from 1999–2000. Phenotypic resistance was examined in all patients, and genotypic resistance was studied in most. High-level phenotypic resistance was defined as a 50% inhibitory concentration (IC50) value exceeding 10-fold higher for the test strain compared to a drug-sensitive reference strain. Results showed that high-level resistance increased from 3.4% in the early period of study to 12.4% in the 1999–2000 period (p = 0.002). The frequency of resistance mutation by genotypic resistance testing increased from 8% in the early period to 22.7% in the more recent period. Data for the outcome of treatment was available in 74% of the 377 participants. This showed that the median time to viral suppression was 56 days in patients with a susceptible virus compared to 88 days for those with a IC50 > 10. Those with a susceptible virus also had a longer period preceding relapse following viral suppression. The results of the resistance assays are summarized in Table 5.TABLE 5Comment: There are now several reports of results of resistance testing showing antiretroviral drug-resistance variance in 1–20% of HIV strains in recently infected patients in North America (JAMA 1999;282:1142;JAMA 1999;282:1135;AIDS 2000;14:F17;AIDS 2002; 16:1511;Lancet 1999;354:729;AIDS 2000;14:1009). Most of these reports show a trend toward increased resistance with sequential analysis that is believed to reflect pressure of antiviral agents. The report by Little and colleagues is particularly strong in two features: First, drug resistance was conservatively defined as an IC50 > 10 relevant to the reference strain; secondly, the authors, for the first time to my knowledge, showed an impact on therapy in terms of time to viral suppression and time to relapse after virologic success (despite knowledge of the resistance profile). This report, combined with the others, is making an increasingly strong argument for routine resistance testing in untreated patients with acute HIV infection or recent seroconversion. This is a policy that is gaining increasing acceptance; however, there is a new controversy surrounding the recommendation that chronically infected patients be tested prior to selection of initial therapy. The difference is the assumed disappearance of resistance strains to “sequestered havens” to give deceptive results. The authors here studied patients up to one year after seroconversion and found no difference in rates of resistance for those who were one year out compared to those with more recent acute infections; the argument is consequently made that resistance testing might be considered in the process of drug selection for any untreated patient.
No takes yet. Share an insight, caveat, or question.
A 2002 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: